BIO International Convention 2019 Permalink
Jinhan Kim, Standigm CEO is supposed to attend the BIO International Convention 2019.
Jinhan Kim, Standigm CEO is supposed to attend the BIO International Convention 2019.
Hee Jung Koo and Daehee Han will attend the BIO Asia International Conference 2019.
Jinhan Kim, Standigm CEO, and Heejung Koo will attend the BIO International Convention 2018.
Jinhan Kim, Standigm CEO, and Daehee Han will attend the BIO Asia International Conference 2018.
Sang Ok Song, Standigm COO, will speak at the 2018 AI Pharma Innovation Drug Discovery.
Heejung Koo will attend at the PMWC 2018 Silicon Valley and present at the AI company showcase .
Jinhan Kim, Standigm CEO will speak at the Bio-Europe 2017 on November 7, 2017. Sang Ok Song, Standigm COO will also attend the meeting. Meet them in Berlin.
Jinhan Kim, Standigm CEO, spoke at Artificial Intelligence in Drug Development Congress 2017.
Jinhan Kim, Standigm CEO, spoke about “artificial applicable intelligence in drug discovery and repositioning” at AI PHARMA INNOVATION.
Jinhan Kim, Standigm CEO, spoke about StandigmAI, the drug repositioning solution, in the Precision Medicine World Conference (PMWC) Silicon Valley.
Executive Summary
SEOUL, South Korea–(BUSINESS WIRE)–Standigm Inc. (“Standigm”), a leading Korean Artificial Intelligence (AI) company for drug discovery, announces today that...
SEOUL, South Korea–(BUSINESS WIRE)–Standigm Inc. (“Standigm”), an artificial intelligence (AI)-based drug discovery company and SK Chemicals Co., Ltd. (“SK C...
SEOUL, South Korea–(BUSINESS WIRE)–Standigm Inc. (“Standigm”), an artificial intelligence (AI)-based drug discovery company, and SK holdings C&C, Co., Lt...
Hyderabad, India and Seoul, South Korea, Tuesday, 15th September, 2020: Standigm Inc., a company using artificial intelligence (AI) technology for drug dis...
The hosted informatics platform will facilitate the advancement of Standigm’s collaborative drug discovery projects
HONG KONG – SK Holdings Co. Ltd. invested KRW10 billion (US$8.6 million) in Standigm Inc., an artificial intelligence (AI)-powered biotech company based in S...
Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has raised 11.5 million dolloar in a Serie...
Standigm is developing drugs for NASH, Parkinson, autism.
Standigm announced today that it has launched two AI-driven drug discovery services, Expander and Hunter. Expander is a service that new and better indicatio...
Standigm and Korea institute of science and technology (KIST) announced a research collaboration to develop a new small molecule medicine for Autism. The dru...
CrystalGenomics, Inc., Standigm’s partner company, today announced a drug predicted by Standigm’s artificial intelligence technology showed the evidence that...
Standigm and Ajou university college of pharmacy announced a research collaboration to develop a new small molecule medicine for Parkinson’s disease. Under t...
Standigm, Inc. and Ajou university medical center today have signed a Memorandum of Understanding (MOU) for developing drug discovery and improving clinical ...
Standigm, Inc. and CrystalGenomics, Inc. today agree collaborative partnership with the objective to discover and develop first-in-class drugs in the multipl...
Standigm, Inc. today announced that it has raised $3 million (3.4 billion won) in seed funding from three capital firms: K-Cube Ventures LLC, LB Investment,...
Standigm had participated in the AstraZeneca-Sanger Drug Combination Prediction Dream Challenge hosted by one of the leading pharmaceutical companies, AstraZ...
Seoul, Korea, South, June 22, 2017 - The advent of artificial intelligence (AI) has global pharmaceutical companies and startups in a race to develop new pro...
Seoul, Korea, South, June 01, 2017 –(PR.com)– CrystalGenomics, Inc. (KOSDAQ: 083790) and Standigm, Inc., today announced the collaborative partnership to app...
K Cube Ventures and BonAngels also made the initial investments in Vuno, Solidware, UVify and Standigm as well as Lunit.
Seoul, Korea, South, February 05, 2016- On February 4th, Standigm, an artificial intelligence and systems biology-based startup, announced that it attracted ...